Drug Profile
TEV 48107
Alternative Names: TEV-48107Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Antibronchitics; Bronchodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Israel (Inhalation)
- 31 Jul 2015 Phase-I clinical trials in Chronic obstructive pulmonary disease in Israel (Inhalation)